Email | Print    Type Size  -  +

Silicon Valley's hottest startup

Pacific Biosciences' groundbreaking gene-sequencing technology could change healthcare.

By Michael V. Copeland, senior writer
Last Updated: October 16, 2008: 2:29 PM ET

pacific_biosciences.03.jpg
Pacific Biosciences aims to make personalized medicine a reality with its gene-sequencing machine.

SAN FRANCISCO (Fortune) -- Silicon Valley operates on potential. Employers may not like it, but talented engineers switch jobs like Pony Express horses so they can be at a company that has a shot at dominating the future. Google (GOOG, Fortune 500) and Apple (AAPL, Fortune 500) (after the return of Steve Jobs) were those kinds of companies. Today, places like Facebook have people lined up knocking on the door to get in.

In health science, Menlo Park, Calif.-based Pacific Biosciences is a company that startup people are willing to leave hefty jobs for because it sits on so much potential. "I can poach people from any company in the Valley," CEO Hugh Martin says with a smile, "and I am."

PacBio as it's known, is building a next generation gene-sequencing machine. The goal of the three-and-a-half-year-old company is to bring gene sequencing to the masses, making it fast and cheap enough to really deliver on the promise of personalized medicine. If PacBio can get it right, it will change healthcare as we know it. That's part of the reason its parking lot is overflowing with new employees (there are more than 200 people at the company). The other reason is that if it can pull it off, the company's investors and its employees stand to make a bundle.

Over the summer, PacBio raised $100 million in funding in its fifth round of financing. The company added Deerfield Management, Intel Capital and other new investors to its initial venture capital backers, which included, among others, Mohr Davidow Ventures and Kleiner Perkins Caufield & Byers. The money is being put toward commercializing the company's technology, which to simplify greatly, eavesdrops on the natural process of DNA replication to ultimately recreate all 6 billion base pairs contained in a complete human genome.

The key for PacBio is to scale up the speed and accuracy of its sequencer to rival nature. So far so good, says PacBio CTO Steve Turner. The PacBio machine has been working out on a little virus called PhiX174, which contains 5,800 base pairs, and has been the first organism to be fully sequenced by the startup's technology.

"The virus we are using for these tests is like a piece of exercise equipment," Turner says. "We can use it over and over to improve the system." The first commercial sequencing machine from PacBio is set to hit the market in 2010. To top of page

Company Price Change % Change
Bank of America Corp... 16.15 0.00 0.00%
Facebook Inc 58.94 0.00 0.00%
General Electric Co 26.56 0.00 0.00%
Cisco Systems Inc 23.19 -0.02 -0.09%
Micron Technology In... 23.91 0.00 0.00%
Data as of Apr 17
Index Last Change % Change
Dow 16,408.54 -16.31 -0.10%
Nasdaq 4,095.52 9.29 0.23%
S&P 500 1,864.85 2.54 0.14%
Treasuries 2.72 0.08 3.19%
Data as of 3:41am ET
More Galleries
50 years of the Ford Mustang Take a drive down memory lane with our favorite photos of the car through the years. More
Cool cars from the New York Auto Show These are some of the most interesting new models and concept vehicles from the Big Apple's car show. More
8 CEOs who took a pay cut in 2013 Median CEO pay inched up 9% in 2013 to $13.9 million. But not everyone got a bump last year. Here are eight CEOs who missed out. More
Sponsors
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.